| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
After extensive analysis, it is demonstrated that FDI-6 binds directly to the FOXM1 protein in MCF-7 breast cancer cells, displacing it from its genetic sites and causing hydrolysis as a result. After three hours of FDI-6 treatment, MDA-MB-231 ER breast cancer and PEO-1 breast cancer show significant modulation of CDC25B. Both types of breast cancer are susceptible to FDI-6 in cell viability (GI50=21.8 μM and 18.1 μM, respectively). of. These genes are networked and essential for G2/M transition, chromosomal segregation, and mitotic spindle integration; their absence triggers the cell killer cycle. Significantly, it has been demonstrated that abnormal overexpression of FOXM1 is a major role in the course of cancer and has been suggested as the initial cause of carcinogenesis [1].
|
|---|---|
| References |
| Molecular Formula |
C19H11F4N3OS2
|
|---|---|
| Molecular Weight |
437.43
|
| Exact Mass |
437.028
|
| CAS # |
313380-27-7
|
| PubChem CID |
5175738
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
6.671
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
29
|
| Complexity |
603
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZATJMMZPGVDUOM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H11F4N3OS2/c20-9-3-5-10(6-4-9)25-17(27)16-15(24)14-11(19(21,22)23)8-12(26-18(14)29-16)13-2-1-7-28-13/h1-8H,24H2,(H,25,27)
|
| Chemical Name |
3-Amino-N-(4-fluorophenyl)-6-thiophen-2-yl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide
|
| Synonyms |
FDI-6 FDI6FDI 6 NCGC-00099374 NCGC 00099374NCGC00099374
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~41.67 mg/mL (~95.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.72 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2861 mL | 11.4304 mL | 22.8608 mL | |
| 5 mM | 0.4572 mL | 2.2861 mL | 4.5722 mL | |
| 10 mM | 0.2286 mL | 1.1430 mL | 2.2861 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
